GSK plans to sell its $1 billion stake in Haleon; The World Health Organization says Mpox is no longer a global health emergency; The Food and Drug Administration rejects a biologics license application for a bladder cancer drug from Patrick Soon-Shiong’s ImmunityBio.
Five things for pharma marketers to know: Thursday, May 11, 2023
Proxy advisory firm says Illumina’s CEO, chairman shouldn’t be reelected to the board; Boehringer Ingelheim’s experimental obesity drug is comparable to rivals; White House assembles a team to address drug shortages.
Five things for pharma marketers to know: Wednesday, May 10, 2023
U.S. Preventive Services Task Force says women should now be screened for breast cancer at 40; Johnson & Johnson’s succeeds in a late-stage trial for ulcerative colitis; Google isn’t living up to its pledge to delete location data when people visit abortion clinics, hospitals and shelters.
Five things for pharma marketers to know: Tuesday, May 9, 2023
Eisai to pay $2 billion in Bliss Biopharmaceutical ADC deal; Scientists examine the potential of Ozempic and Wegovy for Alzheimer’s treatments; Exelixis says Lance Willsey is leaving its board amid proxy fight with Farallon Capital.
Five things for pharma marketers to know: Monday, May 8, 2023
WHO declares end to COVID-19 pandemic’s emergency status; FDA reviewers raise concerns about OTC use of Perrigo’s birth control pill; Elon Musk’s brain-implant venture reportedly fills an animal-research oversight board with company insiders.
Five things for pharma marketers to know: Friday, May 5, 2023
Kenvue wows in first day on Wall Street; Novo Nordisk exec says the pharma giant is temporarily restricting its supply of Wegovy; Sandoz signs distribution agreement with Adalvo for exclusive rights to commercialize six products in the U.S.
Five things for pharma marketers to know: Thursday, May 4, 2023
Haleon CFO not surprised by Pfizer plan to sell stake; Vivek Ramaswamy’s presidential campaign rhetoric differs from time as Roivant Sciences CEO; CDC probes COVID-19 outbreak linked to their own conference.
Five things for pharma marketers to know: Wednesday, May 3, 2023
U.S. Surgeon General Vivek Murthy declares loneliness as an epidemic; Travere Therapeutics’ stock slides after the company unveils disappointing kidney drug trial results; The Biden administration will end most of the remaining federal COVID-19 vaccine requirements next week.
Five things for pharma marketers to know: Tuesday, May 2, 2023
Johnson & Johnson’s bladder cancer treatment shows promise in a Phase II study; Acelyrin seeks a valuation of up to $1.5 billion in IPO; The FDA declines to approve Ascendis Pharma’s experimental hormone disorder therapy.
Five things for pharma marketers to know: Monday, May 1, 2023
Bayer chairman wins reelection vote; Tempest Therapeutics touts its experimental liver cancer therapy; ABC News edits an interview with Robert F. Kennedy Jr. to exclude false claims about COVID-19 vaccines.